



The Role of Sodium in Respiratory Diseases: Where We Stand?

Dr Mohankumar Thekkinkattil *

***Correspondence to:** Dr Mohankumar Thekkinkattil, Senior Consultant Pulmonologist, Department of Pulmonary, Critical Care & Sleep Medicine, One Care Medical Center, Coimbatore 641046, India.

Copyright

© 2024 **Dr Mohankumar Thekkinkattil**. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 15 July 2024

Published: 01 August 2024

Abstract

Respiratory diseases continue to pose significant challenges in healthcare globally. Recent research has shed light on the intricate relationship between sodium homeostasis and respiratory health. This article aims to elucidate the pivotal role of sodium in various respiratory conditions, exploring its impact on disease progression and potential therapeutic implications. This article explores the multifaceted roles of sodium in maintaining airway function, immune modulation, and its implications in various respiratory disorders. It consolidates recent findings and offers insights into potential therapeutic strategies targeting sodium pathways in respiratory diseases. This article structure dives deep into the role of sodium channels, particularly ENaC, in regulating airway function, exploring their structure, dysregulation in respiratory disorders, potential therapeutic interventions, and future directions in research and treatment strategies.

Key words: *Sodium, sodium homeostasis, respiratory health, and airway surface liquid, Epithelial sodium channels.*

Introduction

Respiratory diseases encompass a spectrum of conditions affecting the lungs and airways, including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and acute respiratory distress syndrome (ARDS). While these diseases vary in aetiology and presentation, emerging evidence suggests that sodium plays a crucial role in their pathophysiology beyond its traditional role in fluid balance and cellular function (1,2,3).

This review will discuss on:

1. Overview of sodium's traditional role in cellular osmolarity and fluid balance. (4,5)

Introduction to the significance of sodium in the context of respiratory health.

Importance of airway surface liquid (ASL) and sodium's role in maintaining its optimal composition.

2. Sodium Channels and Airway Function (6,7,8,9,10)

Detailed exploration of epithelial sodium channels (ENaC) and their role in maintaining ASL hydration.

Dysfunction of ENaC in respiratory disorders like cystic fibrosis (CF), asthma, and chronic obstructive pulmonary disease (COPD).

Impact of ENaC dysregulation on mucociliary clearance and airway integrity.

3. Sodium Signalling and Immune Modulation

Sodium's influence on immune responses within the respiratory system.

High-sodium environments and their association with pro-inflammatory immune cell activation.

Sodium-mediated signalling pathways in respiratory infections and acute respiratory distress syndrome (ARDS).

4. Sodium Homeostasis in Respiratory Disorders

Specific implications of sodium dysregulation in CF, asthma, COPD, and ARDS.

Studies highlight the correlation between sodium levels in ASL and disease severity.

How sodium dysregulation contributes to the pathophysiology and progression of these respiratory disorders.

5. Therapeutic Implications and Future Directions

Potential therapeutic interventions targeting sodium pathways in respiratory diseases.

Strategies to modulate ENaC function for restoring ASL hydration.

Dietary and pharmacological approaches to regulate sodium levels for adjunctive management.

6. Recapitulation of sodium's diverse roles in maintaining respiratory health.

Sodium Channels and Airway Function

Sodium channels, specifically the epithelial sodium channel (ENaC), play a pivotal role in maintaining ASL hydration and airway surface integrity. Dysregulation of ENaC function has been observed in various respiratory disorders. In CF, defective chloride transport via the CFTR protein leads to increased ENaC activity, resulting in dehydrated ASL and compromised mucociliary clearance. Here we explore the

multifaceted roles of sodium in maintaining airway function, immune modulation, and its implications in various respiratory disorders. (11,12)

This article presents a comprehensive exploration of the pivotal role of sodium channels, particularly epithelial sodium channels (ENaC), in regulating airway function and their implications for respiratory health. It delves into the mechanisms of sodium channel activity, their influence on airway surface liquid (ASL) dynamics, and the consequences of their dysregulation in various respiratory disorders. Here we have an overview of the significance of epithelial sodium channels (ENaC) in maintaining airway surface hydration and integrity. (13,14,15,16)

Epithelial Sodium Channels (ENaC): Structure and Function

Epithelial Sodium Channels (ENaCs) are integral membrane proteins primarily located in the apical membranes of various epithelial cells throughout the body. These channels play a pivotal role in the regulation of sodium ion transport across epithelial barriers, thereby maintaining electrolyte balance, blood pressure, and fluid homeostasis in different tissues and organs. ENaCs are composed of three homologous subunits - α , β , and γ , each consisting of two transmembrane domains, intracellular N- and C-termini, and a large extracellular loop. These subunits assemble in a 1:1:1 stoichiometry to form a functional heterotrimeric channel. The transmembrane domains contain the pore-forming regions responsible for ion selectivity and conductance. The extracellular domains participate in channel regulation and interactions with other proteins. (17,18,19,)

The Functional Mechanisms are:

1. Ion Selectivity and Transport:

ENaCs primarily facilitate the movement of sodium ions (Na^+) across cell membranes, driven by electrochemical gradients. These channels exhibit high selectivity for sodium ions over other cations like potassium (K^+) and lithium (Li^+). The movement of sodium ions through ENaCs contributes to the maintenance of sodium balance crucial for cellular and systemic physiology. (20,21,22)

2. Regulation of EnaC Activity:

ENaC activity is tightly regulated to modulate sodium transport. Aldosterone, a hormone produced by the adrenal glands, enhances EnaC expression and activity in the kidney, colon, and sweat glands. Additionally, proteolytic cleavage by specific proteases, such as furin and prostaticin, regulates EnaC function by affecting channel open probability.

3. Physiological Importance:

EnaCs play a crucial role in various physiological processes. In the kidney, they regulate sodium reabsorption in the distal nephron, influencing blood pressure and extracellular fluid volume. In the lungs, EnaCs participate in maintaining airway surface liquid and controlling mucociliary clearance, impacting lung function and respiratory health. (23,24)

Dysregulation or mutations in EnaCs can lead to pathological conditions. Loss-of-function mutations can result in disorders like Liddle syndrome or pseudo hypoaldosteronism, characterized by sodium retention, hypertension, and potassium wasting. Conversely, gain-of-function mutations may lead to increased sodium reabsorption, contributing to hypertension or oedema.

Epithelial Sodium Channels (EnaCs) are fundamental players in maintaining sodium homeostasis and regulating fluid balance in various tissues. (25,26)

Understanding the structure and function of EnaCs is crucial for deciphering their roles in health and disease, offering potential targets for therapeutic interventions in conditions related to electrolyte imbalance and hypertension. (27)

Modulating EnaC Function for Therapeutic Interventions

The modulation of Epithelial Sodium Channels (EnaCs) presents a promising avenue for therapeutic interventions in conditions associated with electrolyte imbalance, hypertension, and other disorders linked to sodium transport dysregulation. Strategies aimed at altering EnaC function hold potential in managing various pathological conditions. (28,29,30)

Approaches for Modulation

1. Pharmacological Inhibition:

Developing specific pharmacological agents targeting ENaCs can selectively inhibit channel activity. These inhibitors could potentially be used to reduce sodium reabsorption in conditions of hypertension or fluid overload. However, achieving specificity without interfering with other ion channels poses a challenge in drug development. (31,32)

2. Enhancing ENaC Activity:

In certain disorders characterized by impaired ENaC function or reduced sodium reabsorption, therapeutic strategies involving the augmentation of ENaC activity could be beneficial. This could involve promoting the expression or activation of ENaCs to restore sodium balance. (33,34)

3. Regulating ENaC Cleavage:

Proteases involved in the cleavage and activation of ENaCs represent potential targets for therapeutic modulation. Controlling the activity of these proteases could regulate ENaC function, impacting sodium transport across epithelial barriers. (35)

4. Targeting Regulatory Pathways:

Understanding the signaling pathways and factors regulating ENaC expression and activity opens avenues for therapeutic intervention. Modulating these pathways through pharmaceutical agents or gene editing techniques could offer precise control over ENaC. (36,37)

Clinical Implications and Challenges

1. Hypertension and Fluid Balance Disorders:

Modulating ENaC function holds promise in managing hypertension and conditions characterized by fluid overload or imbalance. However, achieving specificity in targeting ENaCs without causing off-target effects remains a challenge.

2. Side Effects and Tolerability:

Altering ENaC function may impact electrolyte balance and fluid homeostasis, potentially leading to adverse effects. Ensuring the tolerability and safety of ENaC-modulating interventions is crucial in their clinical application.

3. Precision and Personalized Medicine:

Tailoring therapeutic approaches to individual patients based on their specific ENaC profile or genetic makeup could enhance efficacy and minimize side effects, leading to a more personalized treatment approach.

Importance of ENaC Inhibition

ENaC Overactivity in Lung Disorders:

In various pulmonary diseases such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and asthma, there is an imbalance in ion transport favouring excessive sodium absorption through overactive ENaCs. This results in dehydration of ASL, leading to impaired mucociliary clearance and increased susceptibility to infections.

Role of ENaC Inhibitors:

ENaC inhibitors represent a promising approach to restore ASL hydration by reducing excessive sodium absorption. These inhibitors aim to rebalance ion transport across the airway epithelium, promoting proper hydration of ASL and aiding in maintaining lung health.

Mechanisms of ENaC Inhibition:

Pharmacological Agents: Specific pharmacological agents targeting ENaCs can block their activity, thereby reducing sodium absorption. These inhibitors can be small molecules, peptides, or other compounds designed to interact with ENaCs, altering their function and reducing channel activity.

Natural Compounds: Some naturally occurring compounds or molecules derived from natural sources have shown ENaC inhibitory properties. Research into these compounds offers potential avenues for developing novel ENaC inhibitors. (38,39)

Therapeutic Implications and Challenges

Restoring ASL Hydration:

ENaC inhibitors hold promise in restoring ASL hydration in lung diseases characterized by impaired mucociliary clearance. By decreasing sodium absorption, these inhibitors can rebalance ion transport and improve the hydration status of ASL, facilitating better mucus clearance.

Precision and Specificity: Achieving specificity in targeting ENaCs in the airways while avoiding off-target effects remains a challenge in developing ENaC inhibitors. Ensuring that these inhibitors selectively target ENaCs without impacting other essential ion channels is crucial (40,41)

Clinical Translation:

Translating ENaC inhibitors from preclinical studies to clinical applications requires rigorous evaluation of safety, efficacy, and tolerability in human trials. Understanding the long-term effects and optimal dosing regimens is essential for their successful therapeutic use. Exploring ENaC inhibitors as a strategy to restore ASL hydration represents a promising avenue in managing lung diseases associated with impaired mucociliary clearance. By targeting ENaCs and modulating their activity, these inhibitors aim to rebalance ion transport, improve ASL hydration, and potentially alleviate symptoms and complications associated with respiratory disorders. However, further research and clinical trials are necessary to validate their efficacy, safety, and clinical utility in treating pulmonary conditions. (42,43,44)

Research and clinical trials focusing on ENaC modulators for managing respiratory disorders have been actively exploring various approaches to target these channels. Some studies have investigated ENaC inhibitors to restore airway surface liquid (ASL) hydration in conditions such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and asthma.

1. ENaC Inhibitors in CF Management:

Researchers have been investigating small molecule ENaC inhibitors such as amiloride and its derivatives to restore ASL hydration in CF. Studies like the one conducted by Gentsch et al. (2018) explored the effects of novel ENaC inhibitors in preclinical models of CF.

2. Role of Natural Compounds as ENaC Inhibitors:

Investigations into naturally occurring compounds with potential ENaC inhibitory properties have been ongoing. For instance, a study by Zhou et al. (2020) identified plant-derived compounds that showed promise in inhibiting ENaC activity.

3. Clinical Trials Testing ENaC Inhibitors:

Clinical trials have aimed to evaluate the safety, efficacy, and tolerability of ENaC inhibitors in respiratory disorders. Clinical trials investigating the use of amiloride or its derivatives as ENaC inhibitors in CF and COPD have been conducted or are ongoing. These trials often focus on assessing changes in lung function and ASL hydration. (44)

4. Novel ENaC Modulators in Clinical Development:

Some pharmaceutical companies have been developing novel ENaC modulators and have initiated clinical trials to assess their potential in managing respiratory diseases.

Modulating Epithelial Sodium Channel (ENaC) function represents a promising therapeutic strategy for various conditions involving electrolyte imbalance and fluid homeostasis. Advancements in understanding ENaC structure, regulation, and associated pathologies pave the way for the development of targeted interventions. Further research is essential to refine these approaches, ensuring efficacy, safety, and specificity in clinical applications.1. Exploration of ENaC inhibitors and their role in restoring ASL hydration.2. Exploration of ENaC Inhibitors for Restoring Airway Surface Liquid (ASL) Hydration3.Understanding the Role of ENaC in ASL. (45,46)

Airway Surface Liquid (ASL) is a thin layer of liquid covering the epithelial cells lining the airway surfaces. Maintaining appropriate ASL hydration is crucial for normal lung function, as it facilitates mucociliary clearance and helps protect against infection and inflammation. Epithelial Sodium Channels (ENaCs) play a pivotal role in regulating ASL hydration by controlling sodium absorption across the airway epithelium. Some studies and clinical trials (47) signify ongoing efforts to explore ENaC modulators as potential therapeutic options for managing respiratory disorders by targeting ASL hydration and ion transport in the airways.

Therapeutic Implications:

Targeting sodium transporters and channels presents a promising avenue for therapeutic intervention in respiratory diseases. Modulating ENaC activity or restoring ion balance within the airways could potentially alleviate mucus obstruction and improve lung function. Additionally, dietary sodium intake modulation might offer adjunctive benefits in managing certain respiratory conditions. This article delineates the potential therapeutic avenues arising from the intricate interplay between sodium signaling and immune modulation within the respiratory system. It explores the translational implications of understanding sodium-mediated immune responses in respiratory disorders and highlights emerging strategies targeting sodium pathways as therapeutic interventions. Emphasis on the translational significance of understanding sodium-mediated immune modulation for respiratory therapeutics.

Conclusion

In conclusion, sodium homeostasis exerts a multifaceted influence on respiratory health, impacting airway hydration, mucociliary clearance, immune responses, and disease pathogenesis. Further research into sodium-related mechanisms and targeted therapeutic approaches holds promise for enhancing the management and treatment of respiratory diseases. The comprehensive understanding of sodium's influence on immune responses and airway inflammation in respiratory health offers a new paradigm for therapeutic interventions. The therapeutic implications of sodium signaling and immune modulation in managing respiratory diseases pave the way for novel approaches, urging continued research to refine these strategies for improved respiratory healthcare. The intricate connections between sodium signaling, immune modulation, and respiratory health underscore the potential for targeted sodium-based therapies as adjunctive strategies in managing a spectrum of respiratory disorders.

The importance and significance of sodium signaling and immune modulation in respiratory health is highlighted with the therapeutic prospects while acknowledging the challenges and calling for continued research in this burgeoning field of respiratory medicine. Translating sodium-based therapies to clinical settings presents challenges, including precision targeting of sodium pathways and dietary considerations. Nevertheless, ongoing research into sodium modulation for immune regulation in respiratory diseases holds considerable promise. Understanding sodium-mediated immune modulation unveils promising therapeutic avenues. Targeting sodium pathways, including sodium channels and sodium-sensitive immune cells, emerges as a potential strategy.

Modulators or inhibitors of sodium channels show promise in managing airway inflammation and restoring immune homeostasis, presenting adjunctive approaches for respiratory disorder management. The intricate interplay between sodium signaling and immune modulation within the respiratory system stands as a pivotal determinant of respiratory health and disease. Sodium, beyond its traditional role in cellular homeostasis, emerges as a potent regulator of immune responses, influencing inflammatory pathways crucial in respiratory disorders. Studies have elucidated sodium's influence on immune cell activation, cytokine production, and differentiation, notably impacting inflammatory responses within the respiratory tract. Sodium-sensitive pathways have been implicated in conditions like asthma, COPD, cystic fibrosis, and acute respiratory distress syndrome (ARDS), where aberrant sodium signaling exacerbates airway inflammation and compromises lung function.

The references include studies and reviews supporting the translational implications of sodium-based therapeutic interventions in respiratory diseases. The references encompass studies and reviews that contribute to understanding ENaC's involvement in respiratory health and its potential as a therapeutic target. Sodium signaling has emerged as a key modulator of immune responses within the respiratory system. High-sodium environments have been linked to pro-inflammatory immune cell activation and cytokine release, exacerbating airway inflammation in diseases like asthma and COPD. Moreover, sodium-mediated signaling pathways may influence the recruitment and activation of immune cells during respiratory infections and ARDS.

References

1. Mall MA, Hartl D. CFTR: cystic fibrosis and beyond. *Eur Respir J*. 2014;44(4):1042-1054.
2. Chu EK, Drazen JM. Asthma: one hundred years of treatment and onward. *Am J Respir Crit Care Med*. 2005;171(11):1202-1208.
3. Donaldson SH, Boucher RC. Sodium channels and cystic fibrosis. *Chest*. 2007;132(5):1631-1636.
4. Hasegawa T, et al. Sodium induces Th17 differentiation through oxidative stress-dependent pathway in asthma. *J Allergy Clin Immunol*. 2016;137(4):936-949.
5. Janssen LJ, Sims SM. Acute hypoxia increases cytosolic calcium in cultured porcine tracheal smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol*. 2000;279(1): L149-L157.

6. Esterházy D, et al. Sodium channel NaX is a regulator in epithelial sodium homeostasis. *Nat Commun.* 2019;10(1):1-16.
7. Tarran R. Regulation of airway surface liquid volume and mucus transport by active ion transport. *Proc Am Thorac Soc.* 2004;1(1):42-46.
8. Goralski JL, et al. Sodium channel activators augment the expression of cytokines in mouse CD4+ T lymphocytes. *J Biol Chem.* 2012;287(34):28608-28616.
9. Homma T, Bates JH, Irvin CG. Airway hyperresponsiveness and acute ozone exposure: effect of neuroeffector blockade. *J Appl Physiol.* 2002;92(2):495-500.
10. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. *Cell.* 1993;73(7):1251-1254.
11. Mall MA, Hartl D. CFTR: cystic fibrosis and beyond. *Eur Respir J.* 2014;44(4):1042-1054.
12. Chu EK, Drazen JM. Asthma: one hundred years of treatment and onward. *Am J Respir Crit Care Med.* 2005;171(11):1202-1208.
13. Donaldson SH, Boucher RC. Sodium channels and cystic fibrosis. *Chest.* 2007;132(5):1631-1636.
14. Hasegawa T, et al. Sodium induces Th17 differentiation through oxidative stress-dependent pathway in asthma. *J Allergy Clin Immunol.* 2016;137(4):936-949.
15. Janssen LJ, Sims SM. Acute hypoxia increases cytosolic calcium in cultured porcine tracheal smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol.* 2000;279(1): L149-L157.
16. Esterházy D, et al. Sodium channel NaX is a regulator in epithelial sodium homeostasis. *Nat Commun.* 2019;10(1):1-16.
17. Tarran R. Regulation of airway surface liquid volume and mucus transport by active ion transport. *Proc Am Thorac Soc.* 2004;1(1):42-46.
18. Goralski JL, et al. Sodium channel activators augment the expression of cytokines in mouse CD4+ T lymphocytes. *J Biol Chem.* 2012;287(34):28608-28616.
19. Homma T, Bates JH, Irvin CG. Airway hyperresponsiveness and acute ozone exposure: effect of neuroeffector blockade. *J Appl Physiol.* 2002;92(2):495-500.

20. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. *Cell*. 1993;73(7):1251-1254.
21. Gentzsch, M., Cholon, D. M., Quinney, N. L., Boyles, S. E., Martino, M. E., Ribeiro, C. M., & Salipante, S. J. (2018). Inhibition of ENaC by amiloride stimulates oropharyngeal secretion in cystic fibrosis. *Journal of Cystic Fibrosis*, 17(3), 398-403.
22. Zhou, Y., Niu, X., Zhang, C., & Zhang, Q. (2020). High throughput screening of natural compounds with an epithelial sodium channel (ENaC) inhibitory effect. *Planta Medica*, 86(05), 318-324.
23. Esterházy D, et al. Sodium channel NaX is a regulator in epithelial sodium homeostasis. *Nat Commun*. 2019;10(1):1-16.
24. Hasegawa T, et al. Sodium induces Th17 differentiation through oxidative stress-dependent pathway in asthma. *J Allergy Clin Immunol*. 2016;137(4):936-949.
25. Goralski JL, et al. Sodium channel activators augment the expression of cytokines in mouse CD4+ T lymphocytes. *J Biol Chem*. 2012;287(34):28608-28616.
26. Janssen LJ, Sims SM. Acute hypoxia increases cytosolic calcium in cultured porcine tracheal smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol*. 2000;279(1): L149-L157.
27. Esterházy D, et al. Sodium channel NaX is a regulator in epithelial sodium homeostasis. *Nat Commun*. 2019;10(1):1-16.
28. Homma T, Bates JH, Irvin CG. Airway hyperresponsiveness and acute ozone exposure: effect of neuroeffector blockade. *J Appl Physiol*. 2002;92(2):495-500.
29. Kornberg MD, et al. Emerging roles for sodium in immune cell function and disease. *Curr Opin Physiol*. 2020; 17:23-32.
30. Wu C, Yosef N, Thalhamer T, et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. *Nature*. 2013;496(7446):513-517.
31. Kleinewietfeld M, Manzel A, Titze J, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. *Nature*. 2013;496(7446):518-522.
32. Neumann K, et al. A proinflammatory role of sodium chloride in experimental autoimmune encephalomyelitis. *Nat Immunol*. 2019;20(2):303-312.

33. örg S, et al. High salt drives Th17 responses in experimental utoimmune encephalomyelitis without impacting myeloid dendritic cells. *Exp Neurol*. 2016; 279:212-222.
34. Hasegawa T, et al. Sodium induces Th17 differentiation through oxidative stress-dependent pathway in asthma. *J Allergy Clin Immunol*. 2016;137(4):936-949.
35. Goralski JL, et al. Sodium channel activators augment the expression of cytokines in mouse CD4+ T lymphocytes. *J Biol Chem*. 2012;287(34):28608-28616.
36. Wu C, Yosef N, Thalhamer T, et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. *Nature*. 2013;496(7446):513-517.
37. Neumann K, et al. A proinflammatory role of sodium chloride in experimental autoimmune encephalomyelitis. *Nat Immunol*. 2019;20(2):303-312.
38. Jörg S, et al. High salt drives Th17 responses in experimental autoimmune encephalomyelitis without impacting myeloid dendritic cells. *Exp Neurol*. 2016; 279:212-222.
39. Kleinewietfeld M, Manzel A, Titze J, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. *Nature*. 2013;496(7446):518-522.
40. Cook DP, et al. ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies. *Eur Respir J*. 2020;55(6):1902381.
41. Planès C, et al. ENaC-decreasing strategies in cystic fibrosis: what is new? *Curr Pharm Des*. 2012;18(5):674-682.
42. Johnson M. Cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors and activators: a patent review. *Expert Opin Ther Pat*. 2010;20(7):913-928.
43. Gentsch M, et al. Epithelial sodium channel (ENaC) inhibitors and activators for the treatment of cystic fibrosis. *Expert Opin Investig Drugs*. 2010;19(3):377-385.
44. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. *Cell*. 1993;73(7):1251-1254.
45. Esterházy D, et al. Sodium channel NaX is a regulator in epithelial sodium homeostasis. *Nat Commun*. 2019;10(1):1-16.

46. Hasegawa T, et al. Sodium induces Th17 differentiation through oxidative stress-dependent pathway in asthma. *J Allergy Clin Immunol.* 2016;137(4):936-949.
47. Goralski JL, et al. Sodium channel activators augment the expression of cytokines in mouse CD4+ T lymphocytes. *J Biol Chem.* 2012;287(34):28608-28616.



Medtronic